Treatment News : Baby Born With HIV Is Functionally Cured

POZ - Health, Life and HIV
Subscribe to:
POZ magazine
E-newsletters
Join POZ: Facebook MySpace Twitter Pinterest
Tumblr Google+ Flickr MySpace
POZ Personals
Sign In / Join
Username:
Password:

Back to home » Treatment News » March 2013

Most Popular Links
Most Popular Lessons

The HIV Life Cycle

Shingles

Herpes Simplex Virus

Syphilis & Neurosyphilis

Treatments for Opportunistic Infections (OIs)

What is AIDS & HIV?

Hepatitis & HIV

15 Years Ago In POZ


More Treatment News

Click here for more news

Have news about HIV? Send press releases, news tips and other announcements to news@poz.com.


emailprint

March 4, 2013

Baby Born With HIV Is Functionally Cured

CROI 2013In a first for HIV medicine, a baby has been functionally cured of HIV after physicians treated the infant with antiretrovirals (ARVs) beginning about 30 hours after the child was born, which is not common, The New York Times reports. Scientists from the Johns Hopkins Center in Baltimore and the University of Massachusetts Medical School in Worcester announced the results of this case study during the opening of the Conference on Retroviruses and Opportunistic Infections (CROI) in Atlanta.

Following further research, this medical breakthrough may revolutionize the care of infants born with HIV around the world, as well as lead to new insights about the formation of viral reservoirs that make curing HIV otherwise so difficult.

To date, only one other known person in the world, the so-called “Berlin Patient,” has been cured of the virus. In his case, it was a sterilizing cure, in which all virus is removed from the body. In the baby's case, the functional cure allows the immune system to control the virus.

Deborah Persaud, MD, associate 
professor of infectious diseases at the Johns Hopkins Children's Center 
and lead author of the report
Deborah Persaud, MD, associate professor of infectious diseases at the Johns Hopkins Children's Center and lead author of the report.
Now 2 years old, the child was born prematurely in rural Mississippi at 35 weeks to an HIV-positive mother who had not received prenatal care or ARVs. The child maintains an undetectable viral load even after remaining off ARVs for 10 months. Due to the high risk of mother-to-child transmission, physicians began the baby on liquid ARV treatment with AZT (zidovudine), Epivir (lamivudine) and Viramune (nevirapine). They confirmed the child's HIV infection on the second day of life with two blood samples that were analyzed through polymerase chain reaction (PCR) testing. Repeat testing confirmed the HIV-positive diagnosis. After one week of life, the infant left the hospital and was kept on a cocktail of AZT (zidovudine), Epivir (lamivudine) and co-formulated Kaletra (lopinavir) with ritonavir, which is the standard treatment for babies born with HIV. While viral load tests initially confirmed the infection, their levels dropped to less than 50 by the child's 29th day of life.

At 18 months of age, the child's ARVs were discontinued for unknown reasons. About half a year later, medical professionals cared for the child again and discovered that the child maintained an undetectable viral load (less than 20) and had no HIV antibodies. After screening the child with a highly sensitive viral RNA and DNA test, the medical team found extremely low viral levels.

“This case suggests that providing antiretroviral therapy within the very first few days of life to infants infected with HIV through their mothers via pregnancy or delivery may prevent HIV from establishing a reservoir, or hiding place, in their bodies and, therefore, achieve a cure for those children,” said Deborah Persaud, MD, associate professor of infectious diseases at the Johns Hopkins Children’s Center, who presented the findings at CROI.

To read the National Institute of Allergy and Infectious Diseases release, click here.

To read the New York Times article, click here.

Search: CROI 2013, Cure, Functional Cure, Johns Hopkins, Deborah Persaud


Scroll down to comment on this story.



Name:

(will display; 2-50 characters)

Email:

(will NOT display)

City:

(will display; optional)

Comment (500 characters left):

(Note: The POZ team reviews all comments before they are posted. Please do not include either ":" or "@" in your comment. The opinions expressed by people providing comments are theirs alone. They do not necessarily reflect the opinions of Smart + Strong, which is not responsible for the accuracy of any of the information supplied by people providing comments.)

Comments require captcha.
Please enter this number for verification:

| Posting Rules



Show comments (20 total)

 
[Go to top]


Join POZ Facebook Twitter Google+ MySpace YouTube Tumblr Flickr
Quick Links
Current Issue

HIV Testing
Safer Sex
Find a Date
Newly Diagnosed
HIV 101
Disclosing Your Status
Starting Treatment
Help Paying for Meds
Search for the Cure
POZ Stories
POZ Opinion
POZ Exclusives
Read the Blogs
Visit the Forums
Job Listings
Events Calendar


    dlw8585
    Fort Lauderdale
    Florida


    Poz_Qt
    Columbus
    Ohio


    hollywoodvers1
    Los Angeles
    California


    clintonjrsyr
    syracuse
    New York
Click here to join POZ Personals!
Ask POZ Pharmacist

Talk to Us
Poll
Do you work with your doc to design your own treatment regimen?
Yes
No

Survey
PrEP Course

more surveys
Contact Us
We welcome your comments!
[ about Smart + Strong | about POZ | POZ advisory board | partner links | advertising policy | advertise/contact us | site map]
© 2014 Smart + Strong. All Rights Reserved. Terms of use and Your privacy.
Smart + Strong® is a registered trademark of CDM Publishing, LLC.